Corporate ProfileWe are a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. Our pipeline is comprised of cell-based therapies for cancer and immune disorders. Our cellular immunotherapies are based on our novel ex vivo cell programming approach, which we apply to modulate the therapeutic function and direct the fate of hematopoietic cells.
- Sep 04 2020Sep042020
- Aug 19 2020Aug192020
Sep222020September 22, 2020 at 10:50 AM EDTSeptember 22, 2020
10:50 AM EDT